Owlstone Medical and Imperial College collaborate to study underlying causes of asthma exacerbations
Breath analysis technology to be used to predict and characterise onset of severe asthma attacks
Owlstone Medical, a diagnostics company, announced it has entered into collaboration with Imperial College London.
The company’s breath analysis technology will be deployed in an ongoing study led by Imperial College to evaluate underlying causes of exacerbations in severe asthma patients.
An estimated 300 million people worldwide suffer from asthma, with 250,000 annual deaths attributed to the disease. The fundamental causes of asthma are not completely understood, however the strongest risk factors for developing asthma are a combination of genetic predisposition with environmental exposure to allergens and irritants including respiratory infections. Predicting and characterising patients who are likely to have an exacerbation despite optimal therapy is a critical step towards guiding patient management and improving outcomes for severe asthma sufferers.
Volatile organic compounds (VOCs) in breath have been shown to correlate to inflammatory subtypes in asthma, and can also discriminate between viral and bacterial infection, which are extremely relevant in treatment optimization. Owlstone Medical uses the Respiration Collector for In Vitro Analysis (ReCIVA), in combination with the Field Asymmetric Ion Mobility Spectrometer (FAIMS) sensor platform, to accurately and selectively detect volatile organic compounds (VOCs) in breath.
Commenting on the study, Fan Chung, Professor of Respiratory Medicine at Imperial College Faculty of Medicine said: “The causes of the exacerbations that occur in those suffering from severe asthma remain a mystery; elucidating these will represent a major advance that could lead to preventive measures and better targeted treatments.”
“VOCs analysis of exacerbations will enable a more rapid translation towards point of care analysis and correct treatment of patients,” added Ian Adcock, Professor of Respiratory Cell & Molecular Biology at the National Heart and Lung Institute, Imperial College
Billy Boyle, co-founder and CEO at Owlstone Medical, said: “Characterising asthma exacerbations and predicting how patients will respond in certain situations will lead to improved treatment regimes, reduced hospital admissions and emergency treatments, and improved quality of life for asthma patients. Owlstone Medical was created specifically to advance our disease breathalyzer and we will be providing both clinical and academic researchers and pharma companies with access to our technology as part of our services offering, to enable the development of more effective treatments and ultimately better patient outcomes.”
Other news from the department research and development
Most read news
More news from our other portals
Last viewed contents
Research that more than meets the eye - New Technique Analyses Blood Flow in Glaucoma Patients
Filming antibiotic resistance in Slow-Motion - X-ray laser European XFEL captures rapid reaction of bacterial enzyme
Bacteria-based biohybrid microrobots on a mission to one day battle cancer - Scientists add artificial components to bacteria for better control and an extra therapeutic effect in seeking and destroying tumor cells
LAUDA appoints Dr. Ralf Hermann as the new General Manager Constant temperature equipment
Screening proteins to expose early signs of illness - Matthias Mann named European Inventor Award 2019 finalist
Analytica Vietnam 2021 postponed from April to October - Exhibitors thus will be able to better plan their trade fair participation
Protein content as a marker for response to therapy in brain cancer - Look into the future in fact seems possible
World Finance 100 Award for Carl Zeiss Microscopy - The Carl Zeiss Microscopy business group is one of the world's 100 financially most successful companies
Analytica 2020 is postponed - New date in the fall of 2020
New Insights into Kidney Disease with Tropical Frog Models - AI analyzes data from light-sheet microscopy
To successfully treat intoxications caused by consumer products, the formulations must be known - BfR and its Committee "Assessment of Intoxications" propose new labelling for identification purposes in emergencies
